Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery
- Conditions
- Chronic Obstructive Pulmonary DiseaseNon Small Cell Lung Cancer
- Interventions
- Drug: Placebo
- Registration Number
- NCT04536675
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
This is a double-blind randomized controlled trial evaluating the effect of perioperative dual bronchodilator therapy on post-operative pulmonary function and health-related quality of life (QoL) in mild-to-moderate less symptomatic COPD patients undergoing lung cancer surgery.
Investigators hypothesized that dual bronchodilator, as compared with placebo, would prevent reduction of pulmonary function after surgical resection and improve postoperative health related QoL.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 204
-
Subjects of men or female over 40 years of age who are scheduled for curative pulmonary lobectomy due to confirmation (or high suspicion) of non-small cell lung cancer (NSCLC)
-
Subjects waiting at least 14 days for scheduled pulmonary lobectomy
-
Subjects who are newly diagnosed with COPD* or who have not used any bronchodilators within the past 3 months, even if they have previously been diagnosed with COPD
- COPD : Post-bronchodilator (Post-BD) FEV1/FVC <0.7 and Post-BD FEV1 ≥70 %predicted (%pred)
-
Subjects with dyspnea of 0 or 1 grade measured by modified Medical Research Council (mMRC)
- Pregnancy: subjects of women who are pregnant, lactating, planning on becoming pregnant during the clinical trial, or of child bearing potential not using contraception methods
- COPD treatment/acute exacerbation: subjects who have been treated with COPD within the past 3 months or have experienced acute exacerbation of COPD within the past 1 month (Acute exacerbation of COPD is defined as the cases requiring antibiotics, oral corticosteroids, emergency treatment, or hospitalization due to at least one symptom from increased breathlessness, sputum volume, or sputum purulence)
- Other pulmonary diseases: subjects who are physician-diagnosed with asthma or Idiopathic Pulmonary Fibrosis (IPF)
- Lung cancer treatment: subjects who have been received neo-adjuvant treatment for lung cancer (chemotherapy, radiotherapy, or concurrent chemo-radiotherapy)
- Other diseases/abnormalities: subjects diagnosed with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities including medical condition corresponding to 'warnings and precautions' (such as coronary artery disease, acute myocardial infarction, cardiac arrhythmia, hypertension, convulsive disorders, thyrotoxicosis, hypokalemia, diabetes, narrow-angle glaucoma, urinary retention, prostatic hyperplasia, bladder-neck obstruction etc.) that are uncontrolled and/or with cancer within 5 years (Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.)
- Abnormal and clinically significant 12-Lead Eletrocardiogram (ECG): subjects with abnormal and clinically significant ECG findings (Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.)
- Contraindications: subjects with a history of allergy or hypersensitivity to any Long-Acting Muscarinic Antagonist (LAMA), Long-Acting Beta-Agonist (LABA), lactose/milk protein, stearic magnesium, with generic problems including galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption, or with contraindication of inhaled anticholinergic-containing drugs
- Mobility: subjects who are not able to walk independently without mobility assistance or other people
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description VI/UME Vilanterol and Umeclidinium Bromide Anoro (Vilanterol 25mcg/Umeclinidium 62.5mcg) in Ellipta device Inhaled through mouth once daily Control Placebo Placebo (including lactose monohydrate) in Ellipta device Inhaled through mouth once daily
- Primary Outcome Measures
Name Time Method Post-bronchodilator FEV1 at 16 weeks Postoperative 16 to 18 weeks (T3) Post-bronchodilator FEV1 (ml) measured at 16 weeks postoperatively
- Secondary Outcome Measures
Name Time Method Difference of predicted postoperative FEV1 and actual postoperative FEV1 at 16 weeks Postoperative 16 to 18 weeks (T3) and baseline (T0) Difference of predicted postoperative FEV1 (% predicted; calculated from baseline post-bronchodilator FEV1 \[T0\] and surgical extent) and actual post-bronchodilator FEV1 (% predicted) at 4 months postoperatively (PPO T3 - actual T3)
Difference of post-bronchodilator FEV1 between baseline and surgery Baseline (T0) and before surgery (T1) Difference of post-bronchodilator FEV1 (ml) at baseline and post-bronchodilator FEV1 (ml) before surgery (T0 - T1)
Difference of post-bronchodilator FEV1 before surgery and at 3 weeks Before surgery (T1) and postoperative 2 to 4 weeks (T2) Difference of post-bronchodilator FEV1 (ml) before surgery and post-bronchodilator FEV1 (ml) at 3 weeks postoperatively (T1 - T2)
Dyspnea and health-related quality of life at postoperative 3 and 16 weeks Postoperative 2 to 4 weeks (T2) and postoperative 16 to 18 weeks (T3) BDI/TDI
Exercise tolerance at postoperative 3 and 16 weeks Postoperative 2 to 4 weeks (T2) and 16 to 18 weeks (T3) 6-minute walk test distance (meter)
Postoperative pulmonary and cardiac complication Within 30 days and 90 days Postoperative pulmonary complications (PPC) occurring within the first 30 postoperative days is defined as any of the following conditions: 1) atelectasis requiring bronchoscopic toileting; 2) pneumonia (at least three among leukocytosis, pulmonary infiltrate or consolidation, fever \[\>38℃\], culture-positive, or use of antibiotics); 3) acute lung injury or acute respiratory distress syndrome (rate of arterial oxygen partial pressure to fractional inspired oxygen \[PaO2/FiO2\] \<300 and bilateral infiltrate seen on chest radiograph without evidence of congestive heart failure or volume overload), or 4) acute exacerbation of chronic obstructive pulmonary disease. Postoperative cardiac complications (PCC) was defined as acute myocardial infarction, ventricular tachycardia/fibrillation, primary cardiac arrest, complete heart block, any cardiac-related death, or atrial arrhythmia associated with the use of anti-arrhythmic drugs or anti-coagulants.
Length of hospital stay From the admission for lung cancer surgery to discharge or death, whichever comes first Length of hospital stay from the admission for lung cancer surgery to discharge or death
COPD Acute exacerbation Between randomization (T0) and postoperative 16 to 18 weeks (T3) Moderate acute exacerbation is defined as a clinic visit and severe acute exacerbations is defined as a hospitalization or an emergency room visit owing to one or more of the following worsening of dyspnea, increased sputum volume and purulent sputum requiring antibiotics and/ or oral corticosteroids.
Compliance Between randomization (T0) and postoperative 16 to 18 weeks (T3) The compliance is defined by the percentage of use during the clinical trial: complete adherence (\>80%), partial adherence (50-80%), low adherence (\<50%).
Trial Locations
- Locations (1)
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of